217 related articles for article (PubMed ID: 24091849)
1. A phase III concurrent chemoradiotherapy trial with cisplatin and paclitaxel or docetaxel or gemcitabine in unresectable non-small cell lung cancer: KASLC 0401.
Oh IJ; Kim KS; Kim YC; Ban HJ; Kwon YS; Kim YI; Lim SC; Chung WK; Nam TK; Song JY; Yoon MS; Ahn SJ
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1247-54. PubMed ID: 24091849
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer.
Jang J; Kim HK; Cho BC; Lee KH; Yun HJ; Woo IS; Song HS; Ryoo HM; Kim CH; Sun DS; Shin JW
Cancer Chemother Pharmacol; 2017 May; 79(5):873-880. PubMed ID: 28341958
[TBL] [Abstract][Full Text] [Related]
3. Predictive factors for survival and correlation to toxicity in advanced Stage III non-small cell lung cancer patients with concurrent chemoradiation.
Kim YH; Ahn SJ; Kim YC; Kim KS; Oh IJ; Ban HJ; Chung WK; Nam TK; Yoon MS; Jeong JU; Song JY
Jpn J Clin Oncol; 2016 Feb; 46(2):144-51. PubMed ID: 26590014
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase II trial of cisplatin, etoposide, and radiation followed by gemcitabine alone or by combined gemcitabine and docetaxel in stage III A/B unresectable non-small cell lung cancer.
Movsas B; Langer CJ; Ross HJ; Wang L; Jotte RM; Feigenberg S; Xu F; Huang CH; Monberg MJ; Obasaju CK
J Thorac Oncol; 2010 May; 5(5):673-9. PubMed ID: 20354453
[TBL] [Abstract][Full Text] [Related]
5. Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105.
Salama JK; Stinchcombe TE; Gu L; Wang X; Morano K; Bogart JA; Crawford JC; Socinski MA; Blackstock AW; Vokes EE;
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e269-74. PubMed ID: 21477940
[TBL] [Abstract][Full Text] [Related]
6. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
7. A phase I trial of weekly docetaxel and cisplatinum combined to concurrent hyperfractionated radiotherapy for non-small cell lung cancer and squamous cell carcinoma of head and neck.
Varveris H; Mazonakis M; Vlachaki M; Kachris S; Lyraraki E; Zoras O; Maris T; Froudarakis M; Velegrakis J; Perysinakis C; Damilakis J; Samonis G
Oncol Rep; 2003; 10(1):185-95. PubMed ID: 12469168
[TBL] [Abstract][Full Text] [Related]
8. A phase I trial of concurrent chemoradiotherapy with non-split administration of docetaxel and cisplatin for dry stage III non-small-cell lung cancer (JCOG9901DI).
Hida N; Okamoto H; Misumi Y; Sato A; Ishii M; Kashizaki F; Shimokawa T; Shimizu T; Watanabe K
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1625-31. PubMed ID: 22565592
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of low-dose paclitaxel with timed thoracic radiotherapy followed by adjuvant gemcitabine and carboplatin in unresectable stage III non-small cell lung cancer.
Zhang J; Gay HA; Russo S; Parent T; Aljumaily R; Walker PR
Lung Cancer; 2014 Jan; 83(1):67-72. PubMed ID: 24246506
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin-docetaxel induction plus concurrent 3-D conformal radiotherapy and weekly chemotherapy for locally advanced non-small cell lung cancer patients: a phase II trial.
Poudenx M; Bondiau PY; Chamorey E; Venissac N; Otto J; Pourel N; Castelnau O; Tessier E; De Surmont Salasc B; Berdah JF; Pop D; Michel C; Mouroux J
Oncology; 2012; 83(6):321-8. PubMed ID: 22986621
[TBL] [Abstract][Full Text] [Related]
11. [A randomized comparative trial of three combined regimens containing cisplatin for treatment of advanced non-small cell lung cancer].
Liu L; Wang XW; Li L; Zhang X; Zhang WD; Yu XJ
Ai Zheng; 2006 Aug; 25(8):990-4. PubMed ID: 16965680
[TBL] [Abstract][Full Text] [Related]
12. Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04.
Ahn JS; Ahn YC; Kim JH; Lee CG; Cho EK; Lee KC; Chen M; Kim DW; Kim HK; Min YJ; Kang JH; Choi JH; Kim SW; Zhu G; Wu YL; Kim SR; Lee KH; Song HS; Choi YL; Sun JM; Jung SH; Ahn MJ; Park K
J Clin Oncol; 2015 Aug; 33(24):2660-6. PubMed ID: 26150444
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase II trial of S-1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non-small cell lung cancer.
Shimokawa T; Yamada K; Tanaka H; Kubota K; Takiguchi Y; Kishi K; Saito H; Hosomi Y; Kato T; Harada D; Otani S; Kasai T; Nakamura Y; Misumi T; Yamanaka T; Okamoto H
Cancer Med; 2021 Jan; 10(2):626-633. PubMed ID: 33319495
[TBL] [Abstract][Full Text] [Related]
14. [Concurrent chemoradiotherapy followed by consolidation chemotherapy and sequential chemoradiotherapy for stage III non-small cell lung cancer: comparison in 93 patients].
Sun WZ; Song LP; Zhang YB; Ai T; Lu JL; Ren J; Gao Y
Nan Fang Yi Ke Da Xue Xue Bao; 2012 Mar; 32(3):362-7. PubMed ID: 22445984
[TBL] [Abstract][Full Text] [Related]
15. Risk and predictors for early radiation pneumonitis in patients with stage III non-small cell lung cancer treated with concurrent or sequential chemoradiotherapy.
Dang J; Li G; Zang S; Zhang S; Yao L
Radiat Oncol; 2014 Jul; 9():172. PubMed ID: 25074618
[TBL] [Abstract][Full Text] [Related]
16. Risk factors of grade ≥ 2 radiation pneumonitis after gemcitabine induction chemotherapy for patients with non-small cell lung cancer.
Sheng L; Cui X; Cheng L; Chen Y; Du X
Radiat Oncol; 2019 Dec; 14(1):229. PubMed ID: 31842910
[TBL] [Abstract][Full Text] [Related]
17. Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC - IFCT 02-01.
Fournel P; Vergnenégre A; Robinet G; Léna H; Gervais R; Le Caer H; Souquet PJ; Chavaillon JM; Bozonnat MC; Daurès JP; Chouaid C; Martel-Lafay I;
Eur J Cancer; 2016 Jan; 52():181-7. PubMed ID: 26689864
[TBL] [Abstract][Full Text] [Related]
18. Phase I/IIa study of cisplatin and gemcitabine as induction chemotherapy followed by concurrent chemoradiotherapy with gemcitabine and paclitaxel for locally advanced non-small-cell lung cancer.
Divers SG; Spencer SA; Carey D; Busby EM; Hyatt MD; Robert F
J Clin Oncol; 2005 Sep; 23(27):6664-73. PubMed ID: 16170174
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of concurrent high-dose three-dimensional conformal radiotherapy with chemotherapy using cisplatin and vinorelbine for unresectable stage III non-small-cell lung cancer.
Sekine I; Sumi M; Ito Y; Horinouchi H; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Kubota K; Tamura T
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):953-9. PubMed ID: 21377282
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105.
Socinski MA; Blackstock AW; Bogart JA; Wang X; Munley M; Rosenman J; Gu L; Masters GA; Ungaro P; Sleeper A; Green M; Miller AA; Vokes EE
J Clin Oncol; 2008 May; 26(15):2457-63. PubMed ID: 18487565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]